Top

Published in:

01-05-2015 | Original Article

Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications

Authors: Ángel F. Remacha, Beatriz Arrizabalaga, Ana Villegas, María Soledad Durán, Lourdes Hermosín, Raquel de Paz, Marta Garcia, Maria Diez Campelo, Guillermo Sanz, On behalf of the IRON-2 Study Group

Published in: Annals of Hematology | Issue 5/2015

Abstract

This study aimed to evaluate the evolution of iron overload, assessed by serum ferritin (SF), in transfusion-dependent lower risk patients with myelodysplastic syndrome (MDS), as well as to describe the occurrence of organ complications, and to analyze its relationship with iron chelation therapy. This observational retrospective study was conducted from March 2010 to March 2011 in 47 Spanish hospitals. A total of 263 patients with lower risk MDS (International Prognostic Scoring System [IPSS] low/intermediate-1 risk or Spanish Prognostic Index [SPI] 0–1 risk), transfusion-dependent, and who had received ≥10 packed red blood cells (PRBC) were included. At MDS diagnosis, patients received a mean of 2.8 ± 3.9 PRBC/month, and 8.7 % of patients showed SF ≥1000 μg/L. Over the course of the disease, patients received a mean of 83.4 ± 83.3 PRBC, and 36.1 % of patients presented SF ≥2500 μg/L. Cardiac, hepatic, endocrine, or arthropathy complications appeared/worsened in 20.2, 11.4, 9.9, and 3.8 % of patients, respectively. According to investigator, iron overload was a main cause of hepatic (70.0 %) and endocrine (26.9 %) complications. A total of 96 (36.5 %) patients received iron chelation therapy for ≥6 months, being deferasirox the most frequent first chelation treatment (71.9 %). Chelation-treated patients showed longer overall survival (p < 0.001), leukemia-free survival (p = 0.007), and cardiac event-free survival (p = 0.017) than non-chelated patients. In multivariable analyses, age (p = 0.011), IPSS (p < 0.001), and chelation treatment (p = 0.015) were predictors for overall survival; IPSS (p = 0.014) and transfusion frequency (p = 0.001) for leukemia-free survival; and chelation treatment (p = 0.040) and Sorror comorbidity index (p = 0.039) for cardiac event-free survival. In conclusion, these results confirm the potential survival benefit of iron chelation therapy and provide additional evidence on the deleterious effect of iron overload in lower risk MDS patients.

Steensma DP, Bennett JM (2006) The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 81(1):104–130. doi:10.4065/81.1.104 CrossRefPubMed

Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M, Nakao S, Nakahata T, Harada M, Murate T, Ozawa K (2007) Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 78(6):487–494. doi:10.1111/j.1600-0609.2007.00842.x CrossRefPubMed

Malcovati L, Della Porta G, Cazzola M (2006) Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 91(12):1588–1590PubMed

Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23(30):7594–7603. doi:10.1200/JCO.2005.01.7038 CrossRefPubMed

Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079–2088PubMed

Bennett JM, Catovsky D, Daniel MÄ, Flandrin G, Galton D, Gralnick HT, Sultan C (1982) Proposals for the classification of the myelodysplasic syndromes. Br J Haematol 51(2):189–199CrossRefPubMed

Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, Irriguible D, San Miguel JF (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74(1):395–408PubMed

Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P (2010) Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 34(7):864–870. doi:10.1016/j.leukres.2009.12.004 CrossRefPubMed

Neukirchen J, Fox F, Kundgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N (2012) Improved survival in MDS patients receiving iron chelation therapy—a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res 36(8):1067–1070. doi:10.1016/j.leukres.2012.04.006 CrossRefPubMed

10.

Komrokji RS, Al Ali NH, Padron E, Lancet JE, List AF (2011) Impact of iron chelation therapy on overall survival and AML transformation in lower risk MDS Patients treated at the Moffitt Cancer Center. Blood 118(21):1196–1197

11.

Leitch HA (2007) Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 31(Suppl 3):S7–9. doi:10.1016/S0145-2126(07)70460-5 CrossRefPubMed

12.

Lyons RM, Marek BJ, Sharma S, Paley C, Esposito J, Garbo L, DiBella N, Garcia-Manero G (2011) 24-month analysis of the impact of chelation on clinical outcomes in a 600 patient registry of lower-risk MDS patients. Blood 118(21):1207–1208

13.

Porter JB (2001) Practical management of iron overload. Br J Haematol 115(2):239–252CrossRefPubMed

14.

Dreyfus F (2008) The deleterious effects of iron overload in patients with myelodysplastic syndromes. Blood Rev 22(Suppl 2):S29–34. doi:10.1016/S0268-960X(08)70006-7 CrossRefPubMed

15.

Gattermann N (2012) Pathophysiological and clinical aspects of iron chelation therapy in MDS. Curr Pharm Des 18(22):3222–3234CrossRefPubMed

16.

Goldberg SL (2007) Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Leuk Res 31(Suppl 3):S16–22. doi:10.1016/S0145-2126(07)70462-9 PubMed

17.

Leitch HA (2011) Controversies surrounding iron chelation therapy for MDS. Blood Rev 25(1):17–31. doi:10.1016/j.blre.2010.09.003 CrossRefPubMed

18.

Della Porta MG, Malcovati L, Travaglino E, Pascutto C, Maffioli M, Invernizzi R, Cazzola M (2007) A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes. Blood 110(11), abstract 24103

19.

Della Porta G, Kuendgen A, Malcovati L, Zipperer E, Pascutto C, Travaglino E (2008) Myelodysplastic syndrome (MDS)-specific comorbidity index for predicting the impact of extra-hematological comorbidities on survival of patients with MDS. Blood 112(11):925–926a

20.

WHO classification of tumours (2008) In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of hematopoietic and lymphoid tissues. IARC Press, Lyon, pp 109–138

21.

Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM (2008) Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 87(9):691–699. doi:10.1007/s00277-008-0499-3 CrossRefPubMed

22.

Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919. doi:10.1182/blood-2005-05-2004 CrossRefPubMedCentralPubMed

23.

Gattermann N (2007) Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res 31(Suppl 3):S10–15. doi:10.1016/S0145-2126(07)70461-7 CrossRefPubMed

24.

Gattermann N (2008) Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 88(1):24–29. doi:10.1007/s12185-008-0118-z CrossRefPubMedCentralPubMed

25.

Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17(12):3835–3849PubMed

26.

Remacha AF, Arrizabalaga B, Del Canizo C, Sanz G, Villegas A (2010) Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. Ann Hematol 89(2):147–154. doi:10.1007/s00277-009-0794-7 CrossRefPubMed

27.

Komrokyi R, Al Ali N, Padras E (2011) Impact of iron chelation therapy on overall survival and AML transformation in lower risk MDS patients treated at the Moffitt Cancer Centre. Blood 118:2776

28.

Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, Laouri M (2010) Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 28(17):2847–2852. doi:10.1200/JCO.2009.25.2395 CrossRefPubMed

29.

Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, Graux C, Trullemans F, Boulet D, Van Eygen K, Noens L, Van Steenweghen S, Lemmens J, Pierre P, D’Hondt R, Ferrant A, Deeren D, Van De Velde A, Wynendaele W, Andre M, De Bock R, Efira A, Breems D, Deweweire A, Geldhof K, Pluymers W, Harrington A, MacDonald K, Abraham I, Ravoet C (2014) Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leuk Res 38(5):557–563. doi:10.1016/j.leukres.2014.02.003 CrossRefPubMed

30.

Lyons RM, Marek BJ, Paley C, Esposito J, Garbo L, DiBella N, Garcia-Manero G (2014) Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Leuk Res 38(2):149–154. doi:10.1016/j.leukres.2013.11.004 CrossRefPubMed

31.

Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25(23):3503–3510. doi:10.1200/JCO.2006.08.5696 CrossRefPubMed

32.

Leitch HA (2011) Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments. Drugs 71(2):155–177. doi:10.2165/11585280-000000000-00000 CrossRefPubMed

33.

Sanz G, Nomdedeu B, Such E, Bernal T, Belkaid M, Ardanaz T, Cervera J (2008) Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 112(11):238–239a

34.

Wang R, Gross CP, Halene S, Ma X (2009) Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 33(12):1594–1598. doi:10.1016/j.leukres.2009.02.005 CrossRefPubMedCentralPubMed

35.

Della Porta G, Malcovati L (2009) Clinical relevance of extra-hematological comorbidity in the management of patients with myelodysplastic syndrome. Haematologica 94(5):602–606CrossRefPubMed

36.

Hoffbrand AV, Taher A, Cappellini MD (2012) How I treat transfusional iron overload. Blood 120(18):3657–3669. doi:10.1182/blood-2012-05-370098 CrossRefPubMed

37.

Buja LM, Roberts WC (1971) Iron in the heart. Etiology and clinical significance. Am J Med 51(2):209–221CrossRefPubMed

38.

Hellstrom-Lindberg E (2005) Management of anemia associated with myelodysplastic syndrome. Semin Hematol 42(2 Suppl 1):S10–13CrossRefPubMed

39.

Gattermann N (2010) How to treat MDS without stem cell transplantation. Biol Blood Marrow Transplant 16(1 Suppl):S30–36. doi:10.1016/j.bbmt.2009.10.017 CrossRefPubMed

Title: Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
Authors: Ángel F. Remacha
Beatriz Arrizabalaga
Ana Villegas
María Soledad Durán
Lourdes Hermosín
Raquel de Paz
Marta Garcia
Maria Diez Campelo
Guillermo Sanz
On behalf of the IRON-2 Study Group
Publication date: 01-05-2015
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 5/2015
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-014-2274-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2015

Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy

Association between early peak temperature and mortality in neutropenic sepsis

Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis

Efficacy of porcine antihuman lymphocyte immunoglobulin compared to rabbit antithymocyte immunoglobulin as a first-line treatment against acquired severe aplastic anemia

Patterns of monocyte subpopulations and their surface expression of HLA-DR during adverse events after hematopoietic stem cell transplantation

WPSS is a strong prognostic indicator for clinical outcome of allogeneic transplant for myelodysplastic syndrome in Southeast Asian patients

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials